Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
Autoimmune phenomena are common in both hepatitis C infection and interferon alfa treatment; however, the development of antiphospholipid syndrome is rare. This article reports the case of a patient who developed antiphospholipid syndrome in addition to cutaneous sarcoidosis in the setting of pegylated interferon alfa and ribavirin treatment for hepatitis C.
Shinohara
Michi M
MM
Division of Dermatology, Department of Medicine, University Washington, Medical Center, Seattle, WA 98195-6524, USA. mshinoha@u.washington.edu
Davis
Claudia
C
Olerud
John
J
D016736:Antiphospholipid Syndrome / Q000139:chemically induced*; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000737:chemistry; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced*
D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin